Advanced Medical Solutions Group PLC (AMS), the UK-based specialist medical device and wound-care company, has disclosed a change in a major shareholder's position following a regulatory notification filed on 19 November 2026. Octopus Investments Limited, the London-registered investment manager, crossed a reporting threshold after its voting rights in AMS fell to 3.9986%, down from a previously notified 4.01%. The TR-1 form, submitted under DTR5 disclosure rules, confirms the threshold was crossed on 18 November 2026, triggering a mandatory notification to the company the following day. Investors may be watching whether this reduction in a significant institutional holding signals any broader shift in sentiment towards the AMS register.
Key Points
- Advanced Medical Solutions Group PLC (AMS), ISIN GB0004536594
- Octopus Investments Limited reduced its voting rights in AMS from 4.01% to 3.9986%, crossing below the 4% reporting threshold on 18 November 2026
- Octopus now holds 8,844,578 voting rights, all held indirectly; no financial instruments are involved in the position
- Investors should watch whether further TR-1 filings indicate continued reduction or stabilisation of Octopus's position in AMS
Octopus Investments Drops to 3.9986% Voting Rights in AMS After Disposal
The TR-1 standard form notification confirms that Octopus Investments Limited, controlled by Octopus Capital Limited and registered at 33 Holborn, London, disposed of sufficient voting rights in Advanced Medical Solutions Group to fall below the 4% disclosure threshold. The resulting position stands at 3.9986%, representing 8,844,578 voting rights held entirely on an indirect basis under DTR5.2.1. No direct voting rights are held, and the notification records zero exposure through financial instruments. The previous notified position stood at 4.01%, meaning the reduction is modest in percentage terms but sufficient to require a fresh regulatory disclosure under UK transparency rules.
All 8,844,578 AMS Votes Held Indirectly Through Octopus Capital Structure
The disclosure reveals that the entire AMS stake held by Octopus Investments Limited is classified as indirect voting rights, with no direct shareholding recorded against the entity itself. The controlling chain runs from Octopus Capital Limited as the ultimate controlling person, through to Octopus Investments Limited as the notifying party. This structure is common among fund management groups, where underlying client funds hold the economic interest. The announcement does not identify which specific fund or funds within the Octopus group hold the AMS shares, nor does it disclose the consideration received for any shares disposed of in reaching the new position.
AMS Operates Across Wound Care and Surgical Segments With a UK-Listed Profile
Advanced Medical Solutions Group is a UK-listed medical device company focused on advanced wound care, haemostats, and surgical products, operating across international markets. The company's products include tissue adhesives and antimicrobial wound dressings used in clinical settings. Major institutional shareholders such as Octopus Investments are therefore significant indicators of professional investor confidence in the AMS growth story. A reduction in holding, even a marginal one, can prompt scrutiny of the broader shareholder register. The company did not disclose any operational or financial updates alongside this regulatory notification.




Please wait processing your request...